

Yeast display platform technology to prepare oral vaccine against lethal H7N9 virus challenge in mice

CURRENT STATUS: ACCEPTED

Microbial Cell Factories  BMC

Han Lei
Imperial College London

✉ hlei@swjtu.edu.cn *Corresponding Author*
ORCID: <https://orcid.org/0000-0002-5156-4258>

Bowen Xie
College of Medicine, Southwest Jiaotong University

Tong Gao
College of Medicine, Southwest Jiaotong University

Qianhong Cen
College of Medicine, Southwest Jiaotong University

Yi Ren
College of Medicine, Southwest Jiaotong University

DOI:

10.21203/rs.2.19910/v1

SUBJECT AREAS

Applied & Industrial Microbiology

KEYWORDS

S.cerevisiae EBY100/pYD5-HA, Yeast display technology, Influenza A pandemic

Abstract

Background Existing methods for preparing influenza vaccines pose the greatest challenge against the threat of highly pandemic avian influenza virus H7N9 outbreak in the poultry and human. Exploring a new strategy for manufacturing and delivering a safe and effective H7N9 vaccine is urgently needed.

Results An alternative approach, proposed here, is to develop influenza an oral H7N9 vaccine based on yeast display technology in a timely manner. Hemagglutinin (HA) of A/Anhui/1/2013 (AH-H7N9) as a model antigen and characterized its expression on the surface of *Saccharomyces cerevisiae* (*S.cerevisiae*) EBY 100. Mice orally administrated with *S.cerevisiae* EBY100/pYD5-HA produced significant titers of IgG antibody as well as significant amounts of cytokines IFN- γ and IL-4. Importantly, *S.cerevisiae* EBY100/pYD5-HA could provide complete immune protection against homologous A/Anhui/1/2013 (AH-H7N9) virus challenge.

Conclusion Our findings suggest that platform based on yeast surface technology provides an alternative approach to prepare a promising influenza H7N9 vaccine candidate that can significantly shorten the preparedness period and result in effective protection against influenza A pandemic.

Keywords: *S.cerevisiae* EBY100/pYD5-HA, Yeast display technology, Influenza A pandemic.

Full-text

Due to technical limitations, full-text HTML conversion of this manuscript could not be completed. However, the manuscript can be downloaded and accessed as a PDF.

Figures




Figure 1

Construction of yeast display vector and analysis of the expression of HA protein. (A) 1 Schematic diagram of yeast expression vector (*S.cerevisiae* EBY100/pYD5-HA) which the displayed 2 protein (HA) was tethered at its C-terminus to Aga2p mating protein through a (G4S)₃ linker. (B) Western 3 blotting analysis. Lane 1: HA glycoprotein. Lane 2: Deglycosylation of HA protein. Lane 3: *S.cerevisiae* 4 EBY100/pYD5 control. Lane 4: Deglycosylation of *S.cerevisiae* EBY100/pYD5. (C) Immunofluorescence 5 microscope, *S.cerevisiae* EBY100/pYD5 (left) and *S.cerevisiae* EBY100/pYD5-HA (right) (magnification 6 400 ×). (D) Flow cytometric analysis, *S.cerevisiae* EBY100/pYD5 (left) and *S.cerevisiae* EBY100/pYD5-7 HA (right).




Figure 2

Antibody response detected by ELISA and Hemagglutination inhibition (HI) assay. (A) HA - 10 specific IgG titers. (B) HI titers. (C) The cellular immune responses were assayed by ELISpot assay. 11 Splenocytes derived from vaccination (n=3/group) were incubated on the IFN- γ or IL-4 capture antibody 12 coated with stimulation of HA peptide. IFN- γ and IL-4 spots were counted. The data are presented as mean $13 \pm$ standard deviation (SD). Asterisk indicates statistical significance compared to *S.cerevisiae* 14 EBY100/pYD5 and PBS groups ($p < 0.05$).




Figure 3

Immune protection conferred by *S.cerevisiae* EBV100/pYD5-HA against lethal H7N9 virus 18 challenge. Mice were intranasally challenged with a lethal dose ($10 \times \text{LD}_{50}$) of A/Anhui/1/2013 (AH-19 H7N9) virus at 2 weeks after the final immunization ($n=10/\text{group}$).

(A) Weight change as a percentage. 20 Bars indicate SDs. (B) Lung viral titers were determined by a plaque assay at day 3 after challenge ($n=3$ of 21 10 challenged mice). (C) Survival rate. Asterisk indicates significant difference compared to *S.cerevisiae* 22 EBV100/pYD5 and PBS groups ($p < 0.05$).